Age-Related NAFLD: The Use Of Probiotics As A Supportive Therapeutic Intervention Part 4
Jun 26, 2023
References (cont.)
107. Azad, M.A.K.; Sarker, M.; Li, T.; Yin, J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. BioMed Res. Int. 2018, 2018, 1–8. [CrossRef]
Glycoside of cistanche can also increase the activity of SOD in heart and liver tissues, and significantly reduce the content of lipofuscin and MDA in each tissue, effectively scavenging various reactive oxygen radicals (OH-, H₂O₂, etc.) and protecting against DNA damage caused by OH-radicals. Cistanche phenylethanoid glycosides have a strong scavenging ability of free radicals, a higher reducing ability than vitamin C, improve the activity of SOD in sperm suspension, reduce the content of MDA, and have a certain protective effect on sperm membrane function. Cistanche polysaccharides can enhance the activity of SOD and GSH-Px in erythrocytes and lung tissues of experimentally senescent mice caused by D-galactose, as well as reduce the content of MDA and collagen in lung and plasma, and increase the content of elastin, have a good scavenging effect on DPPH, prolong the time of hypoxia in senescent mice, improve the activity of SOD in serum, and delay the physiological degeneration of lung in experimentally senescent mice With cellular morphological degeneration, experiments have shown that Cistanche has the good antioxidant ability and has the potential to be a drug to prevent and treat skin aging diseases. At the same time, echinacoside in Cistanche has a significant ability to scavenge DPPH free radicals and has the ability to scavenge reactive oxygen species and prevent free radical-induced collagen degradation, and also has a good repair effect on thymine free radical anion damage.
108. Duncan, S.H.; Flint, H.J. Probiotics and Prebiotics and Health in Ageing Populations. Maturitas 2013, 75, 44–50. [CrossRef] [PubMed]
109. Reid, G.; Jass, J.; Sebulsky, M.T.; McCormick, J.K. Potential Uses of Probiotics in Clinical Practice. Clin. Microbiol. Rev. 2003, 16, 658–672. [CrossRef]
110. Sanklecha, M.; Verma, L.; Pai, U.; Mishra, S.; Maqsood, S.; Birla, A. Lactobacillus Rhamnosus GG Evaluation in Acute Diarrhea (LEAD): An Observational Study. Cureus 2022. [CrossRef]
111. Ishida, Y.; Nakamura, F.; Kanzato, H.; Sawada, D.; Hirata, H.; Nishimura, A.; Kajimoto, O.; Fujiwara, S. Clinical Effects of Lactobacillus Acidophilus Strain L-92 on Perennial Allergic Rhinitis: A Double-Blind, Placebo-Controlled Study. J. Dairy Sci. 2005, 88, 527–533. [CrossRef]
112. Surawicz, C.M.; Elmer, G.W.; Speelman, P.; McFarland, L.V.; Chinn, J.; Van Belle, G. Prevention of Antibiotic-Associated Diarrhea by Saccharomyces boulardii: A Prospective Study. Gastroenterology 1989, 96, 981–988. [CrossRef]
113. Zhang, B.; An, J.; Shimada, T.; Liu, S.; Maeyama, K. Oral Administration of Enterococcus faecalis FK-23 Suppresses Th17 Cell Development and Attenuates Allergic Airway Responses in Mice. Int. J. Mol. Med. 2012, 30, 248–254. [CrossRef]
114. Wang, I.-J.; Wang, J.-Y. Children with Atopic Dermatitis Show Clinical Improvement after Lactobacillus Exposure. Clin. Exp. Allergy 2015, 45, 779–787. [CrossRef] [PubMed]
115. Kim, J.Y.; Kwon, J.H.; Ahn, S.H.; Lee, S.I.; Han, Y.S.; Choi, Y.O.; Lee, S.Y.; Ahn, K.M.; Ji, G.E. Effect of Probiotic Mix (Bifidobacterium Bifidum, Bifidobacterium Lactis, Lactobacillus Acidophilus) in the Primary Prevention of Eczema: A Double-Blind, Randomized, Placebo-Controlled Trial. Pediatric Allergy Immunol. 2010, 21, e386–e393. [CrossRef]
116. Gaziano, R.; Sabbatini, S.; Roselletti, E.; Perito, S.; Monari, C. Saccharomyces Cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Front. Microbiol. 2020, 11, 718. [CrossRef] [PubMed]
117. Homayouni, A.; Bastani, P.; Ziyadi, S.; Mohammad-Alizadeh-Charandabi, S.; Ghalibaf, M.; Mortazavian, A.M.; Mehrabany, E.V. Effects of Probiotics on the Recurrence of Bacterial Vaginosis: A Review. J. Low. Genet. Tract. Dis. 2014, 18, 79–86. [CrossRef] [PubMed]
118. Moludi, J.; Kafil, H.S.; Qaisar, S.A.; Gholizadeh, P.; Alizadeh, M.; Vayghyan, H.J. Effect of Probiotic Supplementation along with Calorie Restriction on Metabolic Endotoxemia, and Inflammation Markers in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial. Nutr. J. 2021, 20, 47. [CrossRef] [PubMed]
119. Yang, B.; Yue, Y.; Chen, Y.; Ding, M.; Li, B.; Wang, L.; Wang, Q.; Stanton, C.; Ross, R.P.; Zhao, J.; et al. Lactobacillus Plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study. Front. Immunol. 2021, 12, 746585. [CrossRef] [PubMed]
120. Gamallat, Y.; Meyiah, A.; Kuugbee, E.D.; Hago, A.M.; Chiwala, G.; Awadasseid, A.; Bamba, D.; Zhang, X.; Shang, X.; Luo, F.; et al. Lactobacillus Rhamnosus Induced Epithelial Cell Apoptosis, Ameliorates Inflammation, and Prevents Colon Cancer Development in an Animal Model. Biomed. Pharmacother. 2016, 83, 536–541. [CrossRef]
121. Kuugbee, E.D.; Shang, X.; Gamallat, Y.; Bamba, D.; Awadasseid, A.; Suliman, M.A.; Zang, S.; Ma, Y.; Chiwala, G.; Xin, Y.; et al. Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer. Dig. Dis. Sci. 2016, 61, 2908–2920. [CrossRef]
122. Boudeau, J.; Glasser, A.-L.; Julien, S.; Colombel, J.-F.; Darfeuille-Michaud, A. Inhibitory Effect of Probiotic Escherichia Coli Strain Nissle 1917 on Adhesion to and Invasion of Intestinal Epithelial Cells by Adherent-Invasive, E. Coli Strains Isolated from Patients with Crohn’s Disease: INHIBITORY EFFECT OF PROBIOTIC E. COLI NISSLE 1917 ON AIEC COLONIZATION. Aliment. Pharmacol. Ther. 2003, 18, 45–56. [CrossRef]
123. Kelesidis, T.; Pothoulakis, C. Efficacy and Safety of the Probiotic Saccharomyces boulardii for the Prevention and Therapy of Gastrointestinal Disorders. Ther. Adv. Gastroenterol. 2012, 5, 111–125. [CrossRef]
124. Yan, F.; Li, N.; Shi, J.; Li, H.; Yue, Y.; Jiao, W.; Wang, N.; Song, Y.; Huo, G.; Li, B. Lactobacillus Acidophilus Alleviates Type 2 Diabetes by Regulating Hepatic Glucose, Lipid Metabolism and Gut Microbiota in Mice. Food Funct. 2019, 10, 5804–5815. [CrossRef]
125. Yang, B.; Huang, Z.; He, Z.; Yue, Y.; Zhou, Y.; Ross, R.P.; Stanton, C.; Zhang, H.; Zhao, J.; Chen, W. Protective Effect of Bifidobacterium Bifidum FSDJN7O5 and Bifidobacterium Breve FHNFQ23M3 on Diarrhea Caused by Enterotoxigenic Escherichia Coli. Food Funct. 2021, 12, 7271–7282. [CrossRef] [PubMed]
126. Sullivan, Å.; Bennet, R.; Viitanen, M.; Palmgren, A.-C.; Nord, C.E. Influence of Lactobacillus F19 on Intestinal Microflora in Children and Elderly Persons and Impact on Helicobacter Pylori Infections. Microb. Ecol. Health Dis. 2002, 14, 17–21. [CrossRef]
127. Hlivak, P.; Odraska, J.; Ferencik, M.; Ebringer, L.; Jahnova, E.; Mikes, Z. One-Year Application of Probiotic Strain Enterococcus Faecium M-74 Decreases Serum Cholesterol Levels. Bratisl Lek Listy 2005, 106, 67–72.
128. Pakdaman, M.N.; Udani, J.K.; Molina, J.P.; Shahani, M. The Effects of the DDS-1 Strain of Lactobacillus on Symptomatic Relief for Lactose Intolerance - a Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial. Nutr. J. 2015, 15, 56. [CrossRef] [PubMed]
129. Lata, J.; Novotný, I.; Pˇríbramská, V.; Juránková, J.; Friˇc, P.; Kroupa, R.; Stib ˚urek, O. The Effect of Probiotics on Gut Flora, Level of Endotoxin and Child–Pugh Score in Cirrhotic Patients: Results of a Double-Blind Randomized Study. Eur. J. Gastroenterol. Hepatol. 2007, 19, 1111–1113. [CrossRef] [PubMed]
130. Lunia, M.K.; Sharma, B.C.; Sharma, P.; Sachdeva, S.; Srivastava, S. Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: A Randomized Controlled Trial. Clin. Gastroenterol. Hepatol. 2014, 12, 1003–1008.e1. [CrossRef]
131. Zhu, G.; Ma, F.; Wang, G.; Wang, Y.; Zhao, J.; Zhang, H.; Chen, W. Bifidobacteria Attenuate the Development of Metabolic Disorders, with Inter- and Intra-Species Differences. Food Funct. 2018, 9, 3509–3522. [CrossRef]
132. Sohn, M.; Na, G.Y.; Chu, J.; Joung, H.; Kim, B.-K.; Lim, S. Efficacy and Safety of Lactobacillus Plantarum K50 on Lipids in Koreans with Obesity: A Randomized, Double-Blind Controlled Clinical Trial. Front. Endocrinol. 2022, 12, 790046. [CrossRef]
133. Anukam, K.C.; Hayes, K.; Summers, K.; Reid, G. Probiotic Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 May Help Downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (P70) in the Neurogenic Bladder of Spinal Cord Injured Patient with Urinary Tract Infections: A Two-Case Study. Adv. Urol. 2009, 2009, 1–5. [CrossRef]
134. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A review on anti-aging properties of probiotics. Int. J. App. Pharm. 2018, 10, 23. [CrossRef]
135. Salazar, N.; Valdés-Varela, L.; González, S.; Gueimonde, M.; de los Reyes-Gavilán, C.G. Nutrition and the Gut Microbiome in the Elderly. Gut Microbes 2017, 8, 82–97. [CrossRef] [PubMed]
136. Lahtinen, S.J.; Tammela, L.; Korpela, J.; Parhiala, R.; Ahokoski, H.; Mykkänen, H.; Salminen, S.J. Probiotics Modulate the Bifidobacterium Microbiota of Elderly Nursing Home Residents. AGE 2009, 31, 59–66. [CrossRef] [PubMed]
137. Rampelli, S.; Candela, M.; Severgnini, M.; Biagi, E.; Turroni, S.; Roselli, M.; Carnevali, P.; Donini, L.; Brigidi, P. A ProbioticsContaining Biscuit Modulates the Intestinal Microbiota in the Elderly. J. Nutr. Health Aging 2013, 17, 166–172. [CrossRef] [PubMed]
138. Valentini, L.; Pinto, A.; Bourdel-Marchasson, I.; Ostan, R.; Brigidi, P.; Turroni, S.; Hrelia, S.; Hrelia, P.; Bereswill, S.; Fischer, A.; et al. Impact of Personalized Diet and Probiotic Supplementation on Inflammation, Nutritional Parameters and Intestinal Microbiota—The “RISTOMED Project”: Randomized Controlled Trial in Healthy Older People. Clin. Nutr. 2015, 34, 593–602. [CrossRef]
139. Ahmed, M.; Prasad, J.; Gill, H.; Stevenson, L.; Gopal, P. Impact of Consumption of Different Levels of Bifidobacterium Lactis HN019 on the Intestinal Microflora of Elderly Human Subjects. J. Nutr. Health Aging 2007, 11, 26–31.
140. Azad, M.A.K.; Sarker, M.; Wan, D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. BioMed Res. Int. 2018, 2018, 8063647. [CrossRef]
141. María Remes-Troche, J.; Coss-Adame, E.; Ángel Valdovinos-Díaz, M.; Gómez-Escudero, O.; Eugenia Icaza-Chávez, M.; Antonio Chávez-Barrera, J.; Zárate-Mondragón, F.; Antonio Velarde-Ruíz Velasco, J.; Rafael Aceves-Tavares, G.; Antonio Lira-Pedrín, M.; et al. Lactobacillus Acidophilus LB: A Useful Pharmabiotic for the Treatment of Digestive Disorders. Ther. Adv. Gastroenterol. 2020, 13, 175628482097120. [CrossRef]
142. Sánchez, B.; Delgado, S.; Blanco-Míguez, A.; Lourenço, A.; Gueimonde, M.; Margolles, A. Probiotics, Gut Microbiota, and Their Influence on Host Health and Disease. Mol. Nutr. Food Res. 2017, 61, 1600240. [CrossRef]
143. Hemarajata, P.; Versalovic, J. Effects of Probiotics on Gut Microbiota: Mechanisms of Intestinal Immunomodulation and Neuromodulation. Ther. Adv. Gastroenterol. 2013, 6, 39–51. [CrossRef]
144. Chen, L.; Li, H.; Li, J.; Chen, Y.; Yang, Y. Lactobacillus Rhamnosus GG Treatment Improves Intestinal Permeability and Modulates Microbiota Dysbiosis in an Experimental Model of Sepsis. Int. J. Mol. Med. 2019. [CrossRef] [PubMed]
145. Forsyth, C.B.; Farhadi, A.; Jakate, S.M.; Tang, Y.; Shaikh, M.; Keshavarzian, A. Lactobacillus GG Treatment Ameliorates AlcoholInduced Intestinal Oxidative Stress, Gut Leakiness, and Liver Injury in a Rat Model of Alcoholic Steatohepatitis. Alcohol 2009, 43, 163–172. [CrossRef] [PubMed]
146. Tao, Y.; Drabik, K.A.; Waypa, T.S.; Musch, M.W.; Alverdy, J.C.; Schneewind, O.; Chang, E.B.; Petrof, E.O. Soluble Factors from Lactobacillus GG Activate MAPKs and Induce Cytoprotective Heat Shock Proteins in Intestinal Epithelial Cells. Am. J. Physiol.-Cell Physiol. 2006, 290, C1018–C1030. [CrossRef] [PubMed]
147. Park, J.-S.; Choi, J.W.; Jhun, J.; Kwon, J.Y.; Lee, B.-I.; Yang, C.W.; Park, S.-H.; Cho, M.-L. Lactobacillus Acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development. J. Med. Food 2018, 21, 215–224. [CrossRef]
148. Vemuri, R.; Shinde, T.; Gundamaraju, R.; Gondola, S.; Karpe, A.; Beale, D.; Martoni, C.; Eri, R. Lactobacillus Acidophilus DDS-1 Modulates the Gut Microbiota and Improves Metabolic Profiles in Aging Mice. Nutrients 2018, 10, 1255. [CrossRef]
149. Li, X.; Huang, Y.; Song, L.; Xiao, Y.; Lu, S.; Xu, J.; Li, J.; Ren, Z. Lactobacillus Plantarum Prevents Obesity via Modulation of Gut Microbiota and Metabolites in High-Fat Feeding Mice. J. Funct. Foods 2020, 73, 104103. [CrossRef]
150. Graziani, C.; Petito, V.; Del Chierico, F.; Mangiola, F.; Pecere, S.; Schiavoni, E.; Pizzoferrato, M.; Lopetuso, L.R.; Putignani, L.; Gasbarrini, A.; et al. P115 Escherichia Coli Nissle 1917 Modulate Gut Microbiota Composition in Ulcerative Colitis Patients. J. Crohn’s Colitis 2017, 11, S133–S134. [CrossRef]
151. Schlee, M.; Wehkamp, J.; Altenhoefer, A.; Oelschlaeger, T.A.; Stange, E.F.; Fellermann, K. Induction of Human β-Defensin 2 by the Probiotic Escherichia Coli Nissle 1917 Is Mediated through Flagellin. Infect. Immun. 2007, 75, 2399–2407. [CrossRef]
152. Everard, A.; Matamoros, S.; Geurts, L.; Delzenne, N.M.; Cani, P.D. Saccharomyces Boulardii Administration Changes Gut Microbiota and Reduces Hepatic Steatosis, Low-Grade Inflammation, and Fat Mass in Obese and Type 2 Diabetic Db/Db Mice. mBio 2014, 5, e01011–e01014. [CrossRef]
153. Grander, C.; Adolph, T.E.; Wieser, V.; Lowe, P.; Wrzosek, L.; Gyongyosi, B.; Ward, D.V.; Grabherr, F.; Gerner, R.R.; Pfister, A.; et al. Recovery of Ethanol-Induced Akkermansia Muciniphila Depletion Ameliorates Alcoholic Liver Disease. Gut 2018, 67, 891–901. [CrossRef]
154. O’Toole, P.W.; Marchesi, J.R.; Hill, C. Next-Generation Probiotics: The Spectrum from Probiotics to Live Biotherapeutics. Nat. Microbiol 2017, 2, 17057. [CrossRef] [PubMed]
155. Yao, M.; Qv, L.; Lu, Y.; Wang, B.; Berglund, B.; Li, L. An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease. Engineering 2021, 7, 679–686. [CrossRef]
156. Roh, Y.S.; Seki, E. Toll-like Receptors in Alcoholic Liver Disease, Non-Alcoholic Steatohepatitis, and Carcinogenesis: The Role of TLR in ALD, NASH, and HCC. J. Gastroenterol. Hepatol. 2013, 28, 38–42. [CrossRef] [PubMed]
157. Wang, W.; Shi, L.P.; Shi, L.; Xu, L. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease. Zhonghua Nei Ke Za Zhi 2018, 57, 101–106. [CrossRef]
158. Wieland, A.; Frank, D.N.; Harnke, B.; Bambha, K. Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. Aliment. Pharm. 2015, 42, 1051–1063. [CrossRef]
159. Mantovani, A.; Dalbeni, A. Treatments for NAFLD: State of Art. Int. J. Mol. Sci. 2021, 22, 2350. [CrossRef]
160. Borrelli, A.; Bonelli, P.; Tuccillo, F.M.; Goldfine, I.D.; Evans, J.L.; Buonaguro, F.M.; Mancini, A. Role of Gut Microbiota and Oxidative Stress in the Progression of Non-Alcoholic Fatty Liver Disease to Hepatocarcinoma: Current and Innovative Therapeutic Approaches. Redox Biol. 2018, 15, 467–479. [CrossRef] [PubMed]
161. Perumpail, B.; Li, A.; John, N.; Sallam, S.; Shah, N.; Kwong, W.; Cholankeril, G.; Kim, D.; Ahmed, A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019, 7, 27. [CrossRef] [PubMed]
162. Lei, K.; Li, Y.; Wang, Y.; Wen, J.; Wu, H.; Yu, D.; Li, W. Effect of Dietary Supplementation of Bacillus Subtilis B10 on Biochemical and Molecular Parameters in the Serum and Liver of High-Fat Diet-Induced Obese Mice. J. Zhejiang Univ. Sci. B 2015, 16, 487–495. [CrossRef]
163. Vajro, P.; Mandato, C.; Veropalumbo, C.; De Micco, I. Probiotics: A Possible Role in Treatment of Adult and Pediatric Non-Alcoholic Fatty Liver Disease. Ann. Hepatol 2013, 12, 161–163. [CrossRef]
164. Li, C.; Nie, S.-P.; Zhu, K.-X.; Ding, Q.; Li, C.; Xiong, T.; Xie, M.-Y. Lactobacillus Plantarum NCU116 Improves Liver Function, Oxidative Stress, and Lipid Metabolism in Rats with High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease. Food Funct. 2014, 5, 3216–3223. [CrossRef] [PubMed]
165. Zhao, Z.; Wang, C.; Zhang, L.; Zhao, Y.; Duan, C.; Zhang, X.; Gao, L.; Li, S. Lactobacillus Plantarum NA136 Improves the Non-Alcoholic Fatty Liver Disease by Modulating the AMPK/Nrf2 Pathway. Appl. Microbiol. Biotechnol. 2019, 103, 5843–5850. [CrossRef]
166. Xin, J.; Zeng, D.; Wang, H.; Ni, X.; Yi, D.; Pan, K.; Jing, B. Preventing Non-Alcoholic Fatty Liver Disease through Lactobacillus Johnsonii BS15 by Attenuating Inflammation and Mitochondrial Injury and Improving Gut Environment in Obese Mice. Appl. Microbiol. Biotechnol. 2014, 98, 6817–6829. [CrossRef] [PubMed]
167. Ritze, Y.; Bárdos, G.; Claus, A.; Ehrmann, V.; Bergheim, I.; Schwiertz, A.; Bischoff, S.C. Lactobacillus Rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice. PLoS ONE 2014, 9, e80169. [CrossRef]
168. Ren, T.; Huang, C.; Cheng, M. Dietary Blueberry and Bifidobacteria Attenuate Nonalcoholic Fatty Liver Disease in Rats by Affecting SIRT1-Mediated Signaling Pathway. Oxidative Med. Cell. Longev. 2014, 2014, 1–12. [CrossRef] [PubMed]
169. Xu, R.; Wan, Y.; Fang, Q.; Lu, W.; Cai, W. Supplementation with Probiotics Modifies Gut Flora and Attenuates Liver Fat Accumulation in Rat Nonalcoh.holic Fatty Liver Disease Model. J. Clin. Biochem. Nutr. 2011, 50, 72–77. [CrossRef] [PubMed]
170. Bubnov, R.V.; Babenko, L.P.; Lazarenko, L.M.; Mokrozub, V.V.; Demchenko, O.A.; Nechypurenko, O.V.; Spivak, M.Y. Comparative Study of Probiotic Effects of Lactobacillus and Bifidobacteria Strains on Cholesterol Levels, Liver Morphology and the Gut Microbiota in Obese Mice. EPMA J. 2017, 8, 357–376. [CrossRef]
171. Xue, L.; He, J.; Gao, N.; Lu, X.; Li, M.; Wu, X.; Liu, Z.; Jin, Y.; Liu, J.; Xu, J.; et al. Probiotics May Delay the Progression of Nonalcoholic Fatty Liver Disease by Restoring the Gut Microbiota Structure and Improving Intestinal Endotoxemia. Sci. Rep. 2017, 7, 45176. [CrossRef]
172. Seo, M.; Inoue, I.; Tanaka, M.; Matsuda, N.; Nakano, T.; Awata, T.; Katayama, S.; Alpers, D.H.; Komoda, T. Clostridium Butyricum MIYAIRI 588 Improves High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats. Dig. Dis. Sci. 2013, 58, 3534–3544. [CrossRef]
173. Ma, X.; Hua, J.; Li, Z. Probiotics Improve High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance by Increasing Hepatic NKT Cells. J. Hepatol. 2008, 49, 821–830. [CrossRef]
174. Li, Z. Probiotics and Antibodies to TNF Inhibit Inflammatory Activity and Improve Nonalcoholic Fatty Liver Disease. Hepatology 2003, 37, 343–350. [CrossRef] [PubMed]
175. Munukka, E.; Rintala, A.; Toivonen, R.; Nylund, M.; Yang, B.; Takanen, A.; Hänninen, A.; Vuopio, J.; Huovinen, P.; Jalkanen, S.; et al. Faecalibacterium Prausnitzii Treatment Improves Hepatic Health and Reduces Adipose Tissue Inflammation in High-Fat Fed Mice. ISME J. 2017, 11, 1667–1679. [CrossRef] [PubMed]
176. Ahn, S.B.; Jun, D.W.; Kang, B.-K.; Lim, J.H.; Lim, S.; Chung, M.-J. Randomized, Double-Blind, Placebo-Controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019, 9, 5688. [CrossRef] [PubMed]
177. Chen, Y.; Feng, R.; Yang, X.; Dai, J.; Huang, M.; Ji, X.; Li, Y.; Okekunle, A.P.; Gao, G.; Onwuka, J.U.; et al. Yogurt Improves Insulin Resistance and Liver Fat in Obese Women with Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Randomized Controlled Trial. Am. J. Clin. Nutr. 2019, 109, 1611–1619. [CrossRef]
178. Sepideh, A.; Karim, P.; Hossein, A.; Leila, R.; Hamdollah, M.; Mohammad, E.G.; Mojtaba, S.; Mohammad, S.; Ghader, G.; Seyed Moayed, A. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J. Am. Coll. Nutr. 2016, 35, 500–505. [CrossRef]
179. Aller, R.; De Luis, D.A.; Izaola, O.; Conde, R.; Gonzalez Sagrado, M.; Primo, D.; De La Fuente, B.; Gonzalez, J. Effect of a Probiotic on Liver Aminotransferases in Nonalcoholic Fatty Liver Disease Patients: A Double-Blind Randomized Clinical Trial. Eur. Rev. Med. Pharm. Sci 2011, 15, 1090–1095.
180. Derosa, G.; Guasti, L.; D’Angelo, A.; Martinotti, C.; Valentino, M.C.; Di Matteo, S.; Bruno, G.M.; Maresca, A.M.; Gaudio, G.V.; Maffioli, P. Probiotic Therapy with VSL#3®in Patients with NAFLD: A Randomized Clinical Trial. Front. Nutr. 2022, 9, 846873. [CrossRef]
181. Shavakhi, A.; Minakari, M.; Firouzian, H.; Assali, R.; Hekmatdoost, A.; Ferns, G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-Alcoholic Steatohepatitis: A Double-Blind Randomized Clinical Trial. Int. J. Prev. Med. 2013, 4, 531–537.
182. Kobyliak, N.; Abenavoli, L.; Mykhalchyshyn, G.; Kononenko, L.; Boccuto, L.; Kyriienko, D.; Dynnyk, O. A Multi-Strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase Levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. JGLD 2018, 27, 41–49. [CrossRef]
183. Mei, L.; Tang, Y.; Li, M.; Yang, P.; Liu, Z.; Yuan, J.; Zheng, P. Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia Obtusifolia, L. Ameliorate Non-Alcoholic Fatty Liver. PLoS ONE 2015, 10, e0138078. [CrossRef]
184. Park, E.-J.; Lee, Y.-S.; Kim, S.M.; Park, G.-S.; Lee, Y.H.; Jeong, D.Y.; Kang, J.; Lee, H.-J. Beneficial Effects of Lactobacillus Plantarum Strains on Non-Alcoholic Fatty Liver Disease in High Fat/High Fructose Diet-Fed Rats. Nutrients 2020, 12, 542. [CrossRef] [PubMed]
185. Yan, Y.; Liu, C.; Zhao, S.; Wang, X.; Wang, J.; Zhang, H.; Wang, Y.; Zhao, G. Probiotic Bifidobacterium Lactis V9 Attenuates Hepatic Steatosis and Inflammation in Rats with Non-Alcoholic Fatty Liver Disease. AMB Expr. 2020, 10, 101. [CrossRef]
186. Nabavi, S.; Rafraf, M.; Somi, M.H.; Homayouni-Rad, A.; Asghari-Jafarabadi, M. Effects of Probiotic Yogurt Consumption on Metabolic Factors in Individuals with Nonalcoholic Fatty Liver Disease. J. Dairy Sci. 2014, 97, 7386–7393. [CrossRef] [PubMed]
187. Duseja, A.; Acharya, S.K.; Mehta, M.; Chhabra, S.; Shalimar, R.S.; Das, A.; Dattagupta, S.; Dhiman, R.K.; Chawla, Y.K. High Potency Multistrain Probiotic Improves Liver Histology in Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomised, Double-Blind, Proof of Concept Study. BMJ Open Gastroenterol. 2019, 6, e000315. [CrossRef] [PubMed]
188. Ma, J.; Zhou, Q.; Li, H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients 2017, 9, 1124. [CrossRef]
189. Fianchi, F.; Liguori, A.; Gasbarrini, A.; Grieco, A.; Miele, L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int. J. Mol. Sci. 2021, 22, 6485. [CrossRef]
190. Gibson, G.R.; Roberfroid, M.B. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995, 125, 1401–1412. [CrossRef]
191. Holscher, H.D. Dietary Fiber and Prebiotics and the Gastrointestinal Microbiota. Gut Microbes 2017, 8, 172–184. [CrossRef]
192. de Vrese, M.; Schrezenmeir, J. Probiotics, Prebiotics, and Synbiotics. Food Biotechnology 2008, 111, 1–66.
193. Chambers, E.S.; Byrne, C.S.; Morrison, D.J.; Murphy, K.G.; Preston, T.; Tedford, C.; Garcia-Perez, I.; Fontana, S.; SerranoContreras, J.I.; Holmes, E.; et al. Dietary Supplementation with Inulin-Propionate Ester or Inulin Improves Insulin Sensitivity in Adults with Overweight and Obesity with Distinct Effects on the Gut Microbiota, Plasma Metabolome, and Systemic Inflammatory Responses: A Randomised Cross-over Trial. Gut 2019, 68, 1430–1438. [CrossRef]
194. Tandon, D.; Haque, M.M.; Gote, M.; Jain, M.; Bhaduri, A.; Dubey, A.K.; Mande, S.S. A Prospective Randomized, Double-Blind, Placebo-Controlled, Dose-Response Relationship Study to Investigate Efficacy of fructo-oligosaccharides (FOS) on Human Gut Microflora. Sci. Rep. 2019, 9, 5473. [CrossRef] [PubMed]
195. Liu, F.; Li, P.; Chen, M.; Luo, Y.; Prabhakar, M.; Zheng, H.; He, Y.; Qi, Q.; Long, H.; Zhang, Y.; et al. Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in Healthy Young Populations. Sci. Rep. 2017, 7, 11789. [CrossRef] [PubMed]
196. Parnell, J.A.; Raman, M.; Rioux, K.P.; Reimer, R.A. The Potential Role of Prebiotic Fibre for Treatment and Management of Non-Alcoholic Fatty Liver Disease and Associated Obesity and Insulin Resistance. Liver Int. 2012, 32, 701–711. [CrossRef] [PubMed]
197. Daubioul, C.A.; Horsmans, Y.; Lambert, P.; Danse, E.; Delzenne, N.M. Effects of Oligofructose on Glucose and Lipid Metabolism in Patients with Nonalcoholic Steatohepatitis: Results of a Pilot Study. Eur. J. Clin. Nutr. 2005, 59, 723–726. [CrossRef] [PubMed]
198. Fan, J.-G. Effect of Lactulose on Establishment of a Rat Non-Alcoholic Steatohepatitis Model. WJG 2005, 11, 5053. [CrossRef] [PubMed]
199. Matsumoto, K.; Ichimura, M.; Tsuneyama, K.; Moritoki, Y.; Tsunashima, H.; Omagari, K.; Hara, M.; Yasuda, I.; Miyakawa, H.; Kikuchi, K. Fructo-Oligosaccharides and Intestinal Barrier Function in a Methionine–Choline-Deficient Mouse Model of Nonalcoholic Steatohepatitis. PLoS ONE 2017, 12, e0175406. [CrossRef] [PubMed]
200. Ebrahimi-Mameghani, M.; Aliashrafi, S.; Javadzadeh, Y.; AsghariJafarabadi, M. The Effect of Chlorella Vulgaris Supplementation on Liver Enzymes, Serum Glucose, and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease. Health Promot. Perspect. 2014. [CrossRef]
201. Javadi, L.; Ghavami, M.; Khoshbaten, M.; Safaiyan, A.; Barzegari, A.; Pourghassem Gargari, B. The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. Iran. Red Crescent. Med. J. 2017, 19. [CrossRef]
202. Vulevic, J.; Juric, A.; Walton, G.E.; Claus, S.P.; Tzortzis, G.; Toward, R.E.; Gibson, G.R. Influence of Galacto-Oligosaccharide Mixture (B-GOS) on Gut Micro.biota, Immune Parameters and Metabonomics in Elderly Persons. Br. J. Nutr. 2015, 114, 586–595. [CrossRef]
203. Vulevic, J.; Drakoularakou, A.; Yaqoob, P.; Tzortzis, G.; Gibson, G.R. Modulation of the Fecal Microflora Profile and Immune Function by a Novel Trans-Galactooligosaccharide Mixture (B-GOS) in Healthy Elderly Volunteers. Am. J. Clin. Nutr. 2008, 88, 1438–1446. [CrossRef]
204. Walton, G.E.; van den Heuvel, E.G.H.M.; Kosters, M.H.W.; Rastall, R.A.; Tuohy, K.M.; Gibson, G.R. A Randomised Crossover Study Investigating the Effects of Galacto-Oligosaccharides on the Faecal Microbiota in Men and Women over 50 Years of Age. Br. J. Nutr. 2012, 107, 1466–1475. [CrossRef]
205. Markowiak, P.; ´Sli˙zewska, K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017, 9, 1021. [CrossRef] [PubMed]
206. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G.; et al. Bifidobacterium Longum with Fructo-Oligosaccharides in Patients with Non-Alcoholic Steatohepatitis. Dig. Dis. Sci. 2012, 57, 545–553. [CrossRef] [PubMed]
207. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Am. J. Clin. Nutr. 2014, 99, 535–542. [CrossRef] [PubMed]
208. Mofidi, F.; Poustchi, H.; Yari, Z.; Nourinayyer, B.; Merat, S.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic Supplementation in Lean Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Randomised, Double-Blind, placebo-controlled, Clinical Trial. Br. J. Nutr. 2017, 117, 662–668. [CrossRef] [PubMed]
209. Scorletti, E.; Afolabi, P.R.; Miles, E.A.; Smith, D.E.; Almehmadi, A.; Alshathry, A.; Childs, C.E.; Del Fabbro, S.; Bilson, J.; Moyses, H.E.; et al. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 2020, 158, 1597–1610.e7. [CrossRef]
210. Ferolla, S.; Couto, C.; Costa-Silva, L.; Armiliato, G.; Pereira, C.; Martins, F.; Ferrari, M.; Vilela, E.; Torres, H.; Cunha, A.; et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016, 8, 397. [CrossRef]
211. Asgharian, A.; Mohammadi, V.; Gholi, Z.; Esmaillzade, A.; Feizi, A.; Askari, G. The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study. Iran. Red Crescent. Med. J. 2017, 19. [CrossRef]
212. Asgharian, A.; Askari, G.; Esmailzade, A.; Feizi, A.; Mohammadi, V. The Effect of Symbiotic Supplementation on Liver Enzymes, c-Reactive Protein and Ultrasound Findings in Patients with Non-Alcoholic Fatty Liver Disease: A Clinical Trial. Int. J. Prev. Med. 2016, 7, 59. [CrossRef]
213. Björklund, M.; Ouwehand, A.C.; Forssten, S.D.; Nikkilä, J.; Tiihonen, K.; Rautonen, N.; Lahtinen, S.J. Gut Microbiota of Healthy Elderly NSAID Users Is Selectively Modified with the Administration of Lactobacillus Acidophilus NCFM and Lactitol. AGE 2012, 34, 987–999. [CrossRef]
214. Macfarlane, S.; Cleary, S.; Bahrami, B.; Reynolds, N.; Macfarlane, G.T. Synbiotic Consumption Changes the Metabolism and Composition of the Gut Microbiota in Older People and Modifies Inflammatory Processes: A Randomised, Double-Blind, Placebo-Controlled Crossover Study. Aliment. Pharm. 2013, 38, 804–816. [CrossRef]
215. Bartosch, S.; Woodmansey, E.J.; Paterson, J.C.M.; McMurdo, M.E.T.; Macfarlane, G.T. Microbiological Effects of Consuming a Synbiotic Containing Bifidobacterium Bifidum, Bifidobacterium Lactis, and Oligofructose in Elderly Persons, Determined by Real-Time Polymerase Chain Reaction and Counting of Viable Bacteria. Clin. Infect. Dis. 2005, 40, 28–37. [CrossRef] [PubMed]
216. Juárez-Fernández, M.; Porras, D.; Petrov, P.; Román-Sagüillo, S.; García-Mediavilla, M.V.; Soluyanova, P.; Martínez-Flórez, S.; González-Gallego, J.; Nistal, E.; Jover, R.; et al. The Synbiotic Combination of Akkermansia Muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants 2021, 10, 2001. [CrossRef]
217. Kim, K.O.; Gluck, M. Fecal Microbiota Transplantation: An Update on Clinical Practice. Clin. Endosc. 2019, 52, 137–143. [CrossRef] [PubMed]
218. Cammarota, G.; Ianiro, G.; Gasbarrini, A. Faecal Microbiota Transplantation in Clinical Practice. Gut 2018, 67, 196.2–197. [CrossRef]
219. Zhou, D.; Pan, Q.; Shen, F.; Cao, H.; Ding, W.; Chen, Y.; Fan, J. Total Fecal Microbiota Transplantation Alleviates High-Fat Diet-Induced Steatohepatitis in Mice via Beneficial Regulation of Gut Microbiota. Sci. Rep. 2017, 7, 1529. [CrossRef]
220. García-Lezana, T.; Raurell, I.; Bravo, M.; Torres-Arauz, M.; Salcedo, M.T.; Santiago, A.; Schoenenberger, A.; Manichanh, C.; Genescà, J.; Martell, M.; et al. Restoration of a Healthy Intestinal Microbiota Normalizes Portal Hypertension in a Rat Model of Nonalcoholic Steatohepatitis: Liver Failure/Cirrhosis/Portal Hypertension. Hepatology 2018, 67, 1485–1498. [CrossRef]
221. Witjes, J.J.; Smits, L.P.; Pekmez, C.T.; Prodan, A.; Meijnikman, A.S.; Troelstra, M.A.; Bouter, K.E.C.; Herrema, H.; Levin, E.; Holleboom, A.G.; et al. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals with Steatohepatitis. Hepatol. Commun. 2020, 4, 1578–1590. [CrossRef] [PubMed]
222. Craven, L.; Rahman, A.; Nair Parvathy, S.; Beaton, M.; Silverman, J.; Qumosani, K.; Hramiak, I.; Hegele, R.; Joy, T.; Meddings, J.; et al. Allogenic Fecal Microbiota Transplantation in Patients with Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am. J. Gastroenterol. 2020, 115, 1055–1065. [CrossRef]
